NeuroPace (NPCE) & The Competition Head to Head Comparison

NeuroPace (NASDAQ:NPCEGet Rating) is one of 213 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare NeuroPace to related businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares NeuroPace and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeuroPace -79.85% -141.26% -26.16%
NeuroPace Competitors -701.72% -62.64% -17.39%

Valuation & Earnings

This table compares NeuroPace and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NeuroPace $45.18 million -$36.08 million -0.24
NeuroPace Competitors $1.15 billion $85.36 million 25.10

NeuroPace’s rivals have higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and price targets for NeuroPace and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroPace 1 1 4 0 2.50
NeuroPace Competitors 1215 4527 7958 221 2.52

NeuroPace presently has a consensus target price of $16.50, indicating a potential upside of 98.32%. As a group, “Surgical & medical instruments” companies have a potential upside of 35.77%. Given NeuroPace’s higher possible upside, equities analysts plainly believe NeuroPace is more favorable than its rivals.

Institutional and Insider Ownership

49.9% of NeuroPace shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 14.5% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

NeuroPace rivals beat NeuroPace on 8 of the 11 factors compared.

NeuroPace Company Profile (Get Rating)

NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.